{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-016797","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.156629+00:00","generated_at":"2026-05-16T02:08:17.028727+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aprea reports second partial response for APR-1051; endometrial cancer with PPP2R1A mutation","bullets":["Second unconfirmed partial response (uPR) at 220 mg dose: 50% tumor shrinkage (RECIST v1.1) and CA-125 drop from 362 to 47 U/mL (-87%).","Both uPRs observed in endometrial cancer patients with PPP2R1A mutations; both remain on therapy with only Grade 1 adverse events.","Total 22 patients dosed (10–220 mg); five stable disease across four tumor types including HPV-positive HNSCC and FBXW7-mutated colon cancer.","First uPR previously reported at 150 mg; data support genomically guided WEE1 inhibition with favorable tolerability to date.","Next data update expected Q2 2026; enrollment continues at 220 mg and expansion in PPP2R1A endometrial and HPV-positive HNSCC."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-016797","json":"https://secwatch.observer/filing/0001104659-26-016797.json","markdown":"https://secwatch.observer/filing/0001104659-26-016797.md","text":"https://secwatch.observer/filing/0001104659-26-016797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926016797/0001104659-26-016797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926016797/tm266669d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:08:17.028727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}